Brevan Howard Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Brevan Howard Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,413	Closed	-$158K	–	1547
2024 Q4	$158K	Buy	+16,413	New	+$85.6K	﹤0.01%	937

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brevan Howard Capital Management's PSTX Position: Q1 2025 in Review

Brevan Howard Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 16,413 shares — an estimated $158K sold.

Brevan Howard Capital Management first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $158K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Brevan Howard Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 16,413 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $158K.
Brevan Howard Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Brevan Howard Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $158K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Brevan Howard Capital Management's 13F filing for Q1 2025, filed 15 May 2025.